Pharmaceutical composition for treating sarcopenia including glucagon-like peptide-1 receptor agonist
US10751392B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 27, 2016 |
| Grant date | Aug 25, 2020 |
| Priority date | — |
| Expiry date | Sep 11, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P21/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are a pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia including glucagon-like peptide-1 (GLP-1), a GLP-1 fragment, a GLP-1 secretion enhancer, a GLP-1 degradation inhibitor, a GLP-1 receptor (GLP-1R) agonist, or exendin-4, and a method of treating muscle atrophy or sarcopenia by using the pharmaceutical composition. When the pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia provided in the present invention is administered to a subject having sarcopenia or muscle atrophy, reduced body weight, skeletal muscle mass, and grip strength, which are caused by sarcopenia or muscle atrophy, and expression levels of genes involved in muscle production may be restored to normal states, and therefore, the composition may be widely applied to the development of effective therapeutic agents for sarcopenia or muscle atrophy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.